特朗普政府表示不计划对外国仿制药征收关税，这一决定涉及美国人每日用药量90%的进口仿制药。 10月8日，白宫和美国商务部的发言人均已确认，政府并未积极讨论在"232条款"国家安全调查框架下对 仿制药征收关税。 这项潜在的豁免意义重大，因为它将影响到占美国人处方药总量约90%的药品，包括抗生素、心脏病药 物等大量依赖进口的日常用药。此前支持豁免的官员担心，对仿制药征税将导致消费者面临价格上涨甚 至药品短缺。 虽然对仿制药征收关税的可能性降低，但特朗普政府并未放弃"制造业回流"的目标。据报道，美国政府 正在考虑是否应发布行政令，为关键仿制药的国内制造商提供联邦拨款或贷款。 这可能涉及使用来自日本等外国政府的资金，这些资金是与特朗普政府关税协议的一部分，尽管这些基 础设施资金尚未建立。 关税范围大幅收窄 将仿制药排除在关税清单外，标志着美国商务部对医药产品展开的"232条款"调查范围出现重大收缩。 特朗普上月在网上发布消息称将于10月1日对品牌药征收100%关税，但未提及仿制药。 然而，最新的政策方向表明，美国政府在如何利用关税工具重塑医药供应链方面采取了更为谨慎的态 度。 政府内部分歧明显 据报道援引知情人士透露 ...

Core Points - The company, Realcan Pharmaceutical Group Co., Ltd., was established in December 2009 and is registered in Yantai, Shandong Province with a registered capital of RMB 1,504.71 million [2][3][7] - The company aims to enhance health services through innovation and compliance, focusing on a digital, integrated, and intelligent pharmaceutical supply chain [8][9] - The company has undergone several rounds of public and private share issuance, with the latest being a non-public offering in 2016 [3][10] Company Structure - The company operates as a joint-stock limited company, with its legal representative being the chairman of the board [4] - The company has a total of 150,471.0471 million shares issued, all of which are ordinary shares [11][12] - The company is governed by its articles of association, which outline the rights and responsibilities of shareholders, directors, and senior management [4][16] Business Operations - The company's business scope includes the sale of various medical and pharmaceutical products, including medical devices, health foods, and agricultural products [9] - The company is committed to fulfilling its social responsibilities as a key player in the national pharmaceutical supply chain [8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, and access company documents [16][17] - Shareholders are required to report any changes in their shareholding that exceed 3% [22][23] - The company has provisions to protect shareholder interests and ensure compliance with legal obligations [19][20]